The Honeybee Venom Major Allergen Api m 10 (Icarapin) and Its Role in Diagnostics and Treatment of Hymenoptera Venom Allergy

Autor(es)

Jakob, Thilo ^[1] ; Rauber, Michele Myriam ^[1] ; Perez-Riverol, Amilcar ^[1] ; Spillner, Edzard ^[2] ; Blank, Simon ^{[3, 4, 5]}

Afiliação do(s) autor(es)

^[1] Justus Liebig Univ Giessen, Dept Dermatol & Allergol, Expt Dermatol & Allergy Res Grp, Giessen - Germany

^[2] Aarhus Univ, Dept Engn Immunol Biotechnol, Aarhus - Denmark

^[3] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Sch Med, Munich - Germany

^[4] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Munich - Germany

^[5] German Ctr Lung Res DZL, Munich - Germany

• Tipo de documento: Artigo de Revisão
• Fonte: CURRENT ALLERGY AND ASTHMA REPORTS; v. 20, n. 9 JUN 16 2020.
• Citações Web of Science: 1

Resumo

Purpose of Review In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging. (AU)

• Processo FAPESP: 17/22405-3 - Identificação e síntese de peptídeos correspondentes a epítopos lineares de células-b de alérgenos do veneno de hymenoptera sociais: desenvolvimento de insumos para diagnóstico e imunoterapia de alergia
• Beneficiário: Amilcar Perez Riverol
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/16212-5 - Proteopeptídeos naturais da fauna, flora e microbiota brasileira como potenciais modelos para o desenvolvimento racional de novos fármacos de uso terapêutico: isolamento, elucidação estrutural, síntese química e ensaios de atividade funcional
• Beneficiário: Mario Sergio Palma
• Modalidade de apoio: Auxílio à Pesquisa - Programa BIOTA - Temático
• Processo FAPESP: 18/24834-1 - Epítopos de células b sintéticos derivados de alérgenos de Hymenoptera de relevância clínica para o melhoramento do diagnóstico molecular e imunoterapia de alergia a venenos de insetos
• Beneficiário: Amilcar Perez Riverol
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado